Population clinical pharmacology of children: general principles

被引:75
作者
Anderson, Brian J.
Allegaert, Karel
Holford, Nicholas H. G.
机构
[1] Auckland Childrens Hosp, CPICU, Auckland, New Zealand
[2] Univ Auckland, Dept Anaesthesiol, Auckland 1, New Zealand
[3] Univ Auckland, Dept Pharmacol & Clin Pharmacol, Auckland 1, New Zealand
[4] Univ Hosp Gasthuisberg, Neonatal Intens Care Unit, B-3000 Louvain, Belgium
关键词
allometry; children; pharmacodynamics; pharmacokinetics; population modelling;
D O I
10.1007/s00431-006-0188-y
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Introduction Population modelling using mixed-effects models provides a means to study variability in drug responses among individuals representative of those for whom the drug will be used clinically. Discussion The advantages of these models in paediatric studies are that they can be used to analyse sparse data, sampling times are not crucial and can be fitted around clinical procedures and individuals with missing data may still be included in the analysis. The introduction of explanatory covariates explains the predictable part of the between-individual variability. Simulations using parameter estimates and their variability can be used to investigate large numbers of children - many more than is possible in studies dealing with real children - for a fraction of the cost, which is an advantage when developing clinical trials. Paediatric population modelling has expanded greatly in the past decade and is now a routine procedure during the development and investigation of drugs. Children have benefitted and will continue to benefit from this approach.
引用
收藏
页码:741 / 746
页数:6
相关论文
共 48 条
  • [1] Role of modelling and simulation in Phase I drug development
    Aarons, L
    Karlsson, MO
    Mentré, F
    Rombout, F
    Steimer, JL
    van Peer, A
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 13 (02) : 115 - 122
  • [2] Limited predictability of amikacin clearance in extreme premature neonates at birth
    Allegaert, K
    Anderson, BJ
    Cossey, V
    Holford, NHG
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 61 (01) : 39 - 48
  • [3] A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children
    Anderson, BJ
    Woollard, GA
    Holford, NHG
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 50 (02) : 125 - 134
  • [4] Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis
    Anderson, BJ
    Pons, G
    Autret-Leca, E
    Allegaert, K
    Boccard, E
    [J]. PEDIATRIC ANESTHESIA, 2005, 15 (04) : 282 - 292
  • [5] Getting the best from pediatric pharmacokinetic data
    Anderson, BJ
    Hansen, TG
    [J]. PEDIATRIC ANESTHESIA, 2004, 14 (09) : 713 - 715
  • [6] Acetaminophen developmental pharmacokinetics in premature neonates and infants - A pooled population analysis
    Anderson, BJ
    van Lingen, RA
    Hansen, TG
    Lin, YC
    Holford, NHG
    [J]. ANESTHESIOLOGY, 2002, 96 (06) : 1336 - 1345
  • [7] Predicting concentrations in children presenting with acetaminophen overdose
    Anderson, BJ
    Holford, NHG
    Armishaw, JC
    Aicken, R
    [J]. JOURNAL OF PEDIATRICS, 1999, 135 (03) : 290 - 295
  • [8] BERDE CB, 1992, ANESTH ANALG, V75, P164
  • [9] The effect of collinearity on parameter estimates in nonlinear mixed effect models
    Bonate, PL
    [J]. PHARMACEUTICAL RESEARCH, 1999, 16 (05) : 709 - 717
  • [10] ACETAMINOPHEN INGESTION IN CHILDHOOD - COST AND RELATIVE RISK OF ALTERNATIVE REFERRAL STRATEGIES
    BOND, GR
    KRENZELOK, EP
    NORMANN, SA
    TENDLER, JD
    MORRISKUKOSKI, CL
    MCCOY, DJ
    THOMPSON, MW
    MCCARTHY, T
    ROBLEZ, J
    TAYLOR, C
    DOLAN, MA
    REQUA, RK
    CURRY, SC
    [J]. JOURNAL OF TOXICOLOGY-CLINICAL TOXICOLOGY, 1994, 32 (05): : 513 - 525